Literature DB >> 33652858

Natural Products Targeting Amyloid Beta in Alzheimer's Disease.

Joo-Hee Lee1, Na-Hyun Ahn1, Su-Bin Choi1, Youngeun Kwon1, Seung-Hoon Yang1.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by severe brain damage and dementia. There are currently few therapeutics to treat this disease, and they can only temporarily alleviate some of the symptoms. The pathogenesis of AD is mainly preceded by accumulation of abnormal amyloid beta (Aβ) aggregates, which are toxic to neurons. Therefore, modulation of the formation of these abnormal aggregates is strongly suggested as the most effective approach to treat AD. In particular, numerous studies on natural products associated with AD, aiming to downregulate Aβ peptides and suppress the formation of abnormal Aβ aggregates, thus reducing neural cell death, are being conducted. Generation of Aβ peptides can be prevented by targeting the secretases involved in Aβ-peptide formation (secretase-dependent). Additionally, blocking the intra- and intermolecular interactions of Aβ peptides can induce conformational changes in abnormal Aβ aggregates, whereby the toxicity can be ameliorated (structure-dependent). In this review, AD-associated natural products which can reduce the accumulation of Aβ peptides via secretase- or structure-dependent pathways, and the current clinical trial states of these products are discussed.

Entities:  

Keywords:  Alzheimer’s disease; amyloid beta; natural products; secretase-dependent; structure-dependent

Mesh:

Substances:

Year:  2021        PMID: 33652858      PMCID: PMC7956407          DOI: 10.3390/ijms22052341

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  74 in total

1.  Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.

Authors:  Annadurai Anandhan; Kuppusamy Tamilselvam; Thangaiyan Radhiga; Shalinee Rao; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Brain Res       Date:  2011-11-13       Impact factor: 3.252

2.  Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model.

Authors:  Fang Fang; Xiaochun Chen; Tianwen Huang; Lih-Fen Lue; John S Luddy; Shirley Shidu Yan
Journal:  Biochim Biophys Acta       Date:  2011-10-12

3.  Determination of stilbenes (delta-viniferin, trans-astringin, trans-piceid, cis- and trans-resveratrol, epsilon-viniferin) in Brazilian wines.

Authors:  Xavier Vitrac; Aurélie Bornet; Regina Vanderlinde; Josep Valls; Tristan Richard; Jean-Claude Delaunay; Jean-Michel Mérillon; Pierre-Louis Teissédre
Journal:  J Agric Food Chem       Date:  2005-07-13       Impact factor: 5.279

4.  Ginsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer's disease model.

Authors:  Fengling Li; Xiqing Wu; Jing Li; Qingliang Niu
Journal:  Mol Med Rep       Date:  2016-04-12       Impact factor: 2.952

5.  Disrupting beta-amyloid aggregation for Alzheimer disease treatment.

Authors:  L D Estrada; C Soto
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

6.  Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion.

Authors:  Masashi Asai; Nobuhisa Iwata; Ayumu Yoshikawa; Yoshimi Aizaki; Shoichi Ishiura; Takaomi C Saido; Kei Maruyama
Journal:  Biochem Biophys Res Commun       Date:  2006-11-15       Impact factor: 3.575

7.  Postischemic administration of Z-Ligustilide ameliorates cognitive dysfunction and brain damage induced by permanent forebrain ischemia in rats.

Authors:  Xi Kuang; Jun-Rong Du; Yan-Xin Liu; Guang-Yi Zhang; Hai-Yan Peng
Journal:  Pharmacol Biochem Behav       Date:  2007-08-24       Impact factor: 3.533

8.  Curcumin Attenuates Amyloid-β Aggregate Toxicity and Modulates Amyloid-β Aggregation Pathway.

Authors:  Arjun Thapa; Stephen D Jett; Eva Y Chi
Journal:  ACS Chem Neurosci       Date:  2015-11-17       Impact factor: 4.418

9.  Resveratrol-mediated cleavage of amyloid β1-42 peptide: potential relevance to Alzheimer's disease.

Authors:  Sarmad Al-Edresi; Izzeddin Alsalahat; Sally Freeman; Harmesh Aojula; Jeffrey Penny
Journal:  Neurobiol Aging       Date:  2020-04-20       Impact factor: 4.673

Review 10.  Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?

Authors:  Derliz Mereles; Werner Hunstein
Journal:  Int J Mol Sci       Date:  2011-08-31       Impact factor: 5.923

View more
  2 in total

Review 1.  Neuroprotective Natural Products for Alzheimer's Disease.

Authors:  Xin Chen; Joshua Drew; Wren Berney; Wei Lei
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

2.  (-)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer's Disease PSEN1 E280A.

Authors:  Viviana Soto-Mercado; Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Biomolecules       Date:  2021-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.